Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2

NCT03129828 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: Ibrutinib and Bortezomib + R-CHOP

Sponsor

Prof. Dr. Clemens Schmitt

Collaborators

[object Object]
[object Object]